- Home
- SNCR vs CRVO Comparison
SNCR vs CRVO Comparison
Compare SNCR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNCR
- CRVO
- Stock Information
- Founded
- SNCR 2000
- CRVO 2001
- Country
- SNCR United States
- CRVO United States
- Employees
- SNCR N/A
- CRVO N/A
- Industry
- SNCR EDP Services
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- SNCR Technology
- CRVO Health Care
- Exchange
- SNCR Nasdaq
- CRVO Nasdaq
- Market Cap
- SNCR 70.9M
- CRVO 67.4M
- IPO Year
- SNCR 2006
- CRVO N/A
- Fundamental
- Price
- SNCR $5.37
- CRVO $10.51
- Analyst Decision
- SNCR Strong Buy
- CRVO Strong Buy
- Analyst Count
- SNCR 1
- CRVO 6
- Target Price
- SNCR $13.00
- CRVO $20.80
- AVG Volume (30 Days)
- SNCR 72.4K
- CRVO 119.1K
- Earning Date
- SNCR 08-11-2025
- CRVO 08-08-2025
- Dividend Yield
- SNCR N/A
- CRVO N/A
- EPS Growth
- SNCR N/A
- CRVO N/A
- EPS
- SNCR N/A
- CRVO N/A
- Revenue
- SNCR $171,870,000.00
- CRVO $7,776,968.00
- Revenue This Year
- SNCR $1.51
- CRVO N/A
- Revenue Next Year
- SNCR $5.43
- CRVO N/A
- P/E Ratio
- SNCR N/A
- CRVO N/A
- Revenue Growth
- SNCR 2.54
- CRVO N/A
- 52 Week Low
- SNCR $5.25
- CRVO $1.80
- 52 Week High
- SNCR $15.46
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- SNCR 29.45
- CRVO 63.06
- Support Level
- SNCR $6.11
- CRVO $9.61
- Resistance Level
- SNCR $6.28
- CRVO $10.89
- Average True Range (ATR)
- SNCR 0.29
- CRVO 0.67
- MACD
- SNCR -0.07
- CRVO 0.04
- Stochastic Oscillator
- SNCR 8.63
- CRVO 70.28
About SNCR Synchronoss Technologies Inc.
Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.